Tyler C. Glass
Associate Corporate & Finance
-
Overview
-
Experience
-
Credentials
-
Insights and events
Tyler Glass knows that good lawyering involves having a good attitude. That is why he strives to serve his clients with initiative and a smile on his face.
As a securities and public company advisory associate in Philadelphia, his practice focuses on advising corporations in the life sciences industry on a broad range of corporate and securities matters, including 33' and 34' Act reporting, Section 16 reporting, Nasdaq and NYSE-related matters, capital market offerings (e.g., ATMs, RDOs, CMPOs, PIPEs), and general corporate governance. Tyler has extensive experience in preparing and reviewing SEC disclosures (e.g., Form 8-K, Form 10-Q, Form 10-K), proxy statements, registration statements, board and committee resolutions, corporate governance presentations and policies, and press releases. Additionally, he regularly advises public clients, including senior executives, boards of directors, finance teams and investor relations teams, on securities, governance, transactional, and a range of other complex issues.
Growing up with the goal of being an attorney while also naturally drawn to the world of business and finance, Tyler finds himself in the fortunate position of being able to blend those two interests in a way that provides excellent service to his clients. A life-long learner, Tyler is not afraid to ask questions and dig into the details of his clients' needs and objectives.
During his time as a law student, Tyler served as a staff editor on the Temple Law Review. Throughout his law school career, he worked as a summer associate at Hogan Lovells as well as a judicial intern for the Honorable Judge Marilyn Heffley in the U.S. District Court for the Eastern District of Pennsylvania.
Representative experience
Perspective Therapeutics (NYSE American: CATX), a clinical-stage radiopharmaceutical company, on its 1-for-10 reverse stock split.
Portage Biotech Inc. (Nasdaq: PRTG), a clinical-stage immuno-oncology company, on its 1-for-20 reverse stock split.
Perspective Therapeutics (NYSE American: CATX), a clinical-stage radiopharmaceutical company, on its $80m underwritten offering of common stock and pre-funded warrants.
Perspective Therapeutics (NYSE American: CATX), a clinical-stage radiopharmaceutical company, on its $87.4m private placement financing led by Oppenheimer & Co.
Perspective Therapeutics (NYSE American: CATX), a clinical-stage radiopharmaceutical company, on its $69m underwritten public follow-on offering and concurrent $20.8m private placement.
Portage Biotech Inc. (Nasdaq: PRTG), a clinical-stage immuno-oncology company, on a registered direct offering and a concurrent private placement led by H.C. Wainwright.
Sesen Bio (Nasdaq: SESN), a clinical life sciences company, on its $36m reverse merger involving special cash and contingent value right dividends and activist shareholder involvement.
Marinus Pharmaceuticals (Nasdaq: MRNS) on its $60m underwritten public offering of equity securities through a syndicate of underwriters led by SVB Securtities, RBC Securities and Cantor.
Several clinical-stage life sciences companies in at-the-market equity offerings led by RBC Capital Markets, Jefferies, JMP Securities, and Cantor Fitzgerald.
Regular corporate governance and securities advice to a wide variety of life sciences public companies.
NextNav Inc. (Nasdaq: NN), a leader in next-generation GPS, on its business combination with Spartacus Acquisition Corp., a special purpose acquisition company.
Credentials
- J.D., Temple University School of Law, magna cum laude, Beasley Scholar, 2020
- B.S. Finance, Pennsylvania State University, 2017
- Pennsylvania